Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Are we sleepwalking into AI disruption in GI?
- AI Digital Twins Are Helping People Manage Diabetes and Obesity (WIRED)
- 3 Healthcare Threats That Will Soon Become Too Big To Solve (Forbes)
- From GLP-1s to engineered probiotics: New research highlights evolving IBD care (AGA)
- Physician consolidation squeeze: Rising costs and tight cash flow are reshaping practice growth (Physicians Practice)
- The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health (Nature Reviews Gastroenterology & Hepatology)
- Medical Malpractice: Staying Out of Trouble (GI & Endoscopy News)
- Evaluating Benefits of AI During Colonoscopy (GI & Endoscopy News)
